Search Results

You are looking at 41 - 50 of 259 items for :

Clear All
Free access

Patricia Vázquez, Isabel Roncero, Enrique Blázquez and Elvira Alvarez

facilitate the action of these proteins involved in the signalling process ( Pawson & Scott 1997 ). The glucagon-like peptide-1 (GLP-1) receptor is a member of the G-protein-coupled receptor subfamily ( Dillon et al. 1993 , Thorens 1993 , Thorens

Free access

Patrice D Cani, Catherine A Daubioul, Brigitte Reusens, Claude Remacle, Grégory Catillon and Nathalie M Delzenne

( Reimer & McBurney 1996 , Cani et al. 2004 ). In the intestine, the post-translational modification of the proglucagon gene by prohormone convertase 1 (PC1) leads to the production of glucagon-like peptide-1(7–36) amide (GLP-1(7–36) amide) which, among

Free access

Hongbin Liu, Anthony E Dear, Lotte B Knudsen and Richard W Simpson

protected from the development of biochemical abnormalities associated with endothelial cell dysfunction and development of atherosclerosis ( Eitzman et al . 2000 , Mao et al . 2004 ). Liraglutide, an acylated glucagon-like peptide-1 (GLP-1) analogue, has

Free access

Bernard Khoo and Tricia Mei-Mei Tan

regain ( King et al. 2019 ). As a result, there is still an unmet need for other approaches to the treatment of obesity and associated T2D. The gut hormones, led by GLP-1, have emerged over the past few years as a potential answer to this need. This

Free access

Catia Martins, Linda M Morgan, Stephen R Bloom and M Denise Robertson

), peptide YY (PYY), glucagon-like peptide-1 (GLP-1) and pancreatic polypeptide (PP) ( Blundell 1991 , King et al. 1997 b ). These metabolic and endocrine signals are then received and processed by specific areas in the hypothalamus and brainstem

Free access

Hong Lan, Galya Vassileva, Aaron Corona, Li Liu, Hana Baker, Andrei Golovko, Susan J Abbondanzo, Weiwen Hu, Shijun Yang, Yun Ning, Robert A Del Vecchio, Frederique Poulet, Maureen Laverty, Eric L Gustafson, Joseph A Hedrick and Timothy J Kowalski

fall into two major categories: drugs that improve insulin sensitivity, and those that increase insulin secretion from β-cells. Agents that enhance insulin secretion in a glucose-dependent manner, such as glucagon-like peptide-1 (GLP-1) mimetics (e

Free access

Shin-ya Ueda, Takahiro Yoshikawa, Yoshihiro Katsura, Tatsuya Usui, Hayato Nakao and Shigeo Fujimoto

endocrine organs, including ghrelin, peptide YY (PYY), pancreatic polypeptide (PP), glucagon-like peptide-1 (GLP-1), cholecystokinin (CCK), and oxyntomodulin ( Huda et al . 2006 , Näslund & Hellstrom 2007 , Wren & Bloom 2007 ). While of these, ghrelin is

Free access

Sara Baldassano, Anna Lisa Bellanca, Rosa Serio and Flavia Mulè

.w.), GLP1 (0.30 μg/g b.w.), GLP2 (3–33) (0.90 μg/g b.w.), exendin (9–39) (0.20 μg/g b.w.), or GLP2 (0.90 μg/g b.w.) in the early light phase (0800–0900 h). Prior to the initial study, mice received a daily i.p. injection of 100 μl PBS for 7 days to

Restricted access

Eun-Young Lee, Xilin Zhang, Junki Miyamoto, Ikuo Kimura, Tomoaki Taknaka, Kenichi Furusawa, Takahito Jomori, Kosuke Fujimoto, Satoshi Uematsu and Takashi Miki

Introduction Oral ingestion of carbohydrate triggers secretion of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), the major incretins that inhibit the rise in blood glucose levels by potentiating insulin

Free access

Sehee Kim, Minho Moon and Seungjoon Park

pharmacological intervention of MMP-3 and microglial activation could be considered as plausible candidates for neuroprotective agents in PD. Glucagon-like peptide-1 (GLP-1), an endogenous 30-amino acid gut–brain peptide hormone, is synthesized from proglucagon